Peptide library / Digestive & weight / Oxyntomodulin
Oxyntomodulin
A natural gut hormone that activates both GLP-1 and glucagon receptors, and inspired later dual agonists.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Reduced appetite in overweight peopleSmall human studies
- Template for dual agonist drugsSmall human studies
How it is thought to work
Oxyntomodulin is released with GLP-1 after meals and reduces appetite while increasing energy expenditure, but is cleared from the body within minutes.
What the evidence shows
A four-week study in overweight volunteers using injections before meals reduced food intake and body weight, but required multiple daily injections.
Safety and unknowns
Nausea and flushing were reported. The natural form is too short-lived to be practical.
Regulatory status
Not approved. Modified, longer-acting versions are the basis of current drug candidates.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Pemvidutide
In clinical trialsAn investigational GLP-1 and glucagon dual agonist from Altimmune, aimed at fatty liver disease.
Petrelintide
In clinical trialsAn investigational long-acting amylin analog from Zealand Pharma and Roche.
Mazdutide
In clinical trialsA dual GLP-1 and glucagon receptor agonist developed by Innovent, approved in China for obesity.
General information, not medical advice. Do not buy or inject unregulated peptides.